LIPO-102: Phase IIb data

A double-blind Phase IIb trial in 164 healthy volunteers with a body mass index (BMI) <=25 kg/m 2 showed that once-weekly subcutaneous LIPO-102 injected into the anterior abdomen for 8 weeks significa...